KDR and cancer: Similarly, ramucirumab, a monoclonal antibody targeting VEGFR-2, has shown efficacy as monotherapy in various cancers, including gastric, hepatocellular carcinoma, colorectal, and non–small cell lung cancers, resulting in its FDA approval (157–161).